2. Signaling Pathways
  3. GPCR/G Protein
    Neuronal Signaling
  4. Neurotensin Receptor
  5. Neurotensin Receptor Inhibitor

Neurotensin Receptor Inhibitor

Neurotensin Receptor Isoform Comparison

Neurotensin Receptor Inhibitors (7):

Cat. No. Product Name Effect Purity
  • HY-12802
    AF38469
    		Inhibitor 99.28%
    AF38469 is a selective, orally bioavailable Sortilin inhibitor with an IC50 value of 330 nM.
  • HY-115213
    SORT-PGRN interaction inhibitor 1
    		Inhibitor 99.17%
    SORT-PGRN interaction inhibitor 1 is a potent inhibitor of the sortilin-progranulin interaction with an IC50 of 2 μM.
  • HY-P99688
    Latozinemab
    		Inhibitor
    Latozinemab (AL001) is a recombinant human anti-Sortilin monoclonal antibody. Latozinemab effectively binds Sortilin with a high affinity and blocks the interaction between progranulin protein (PGRN) and Sortilin receptor. Latozinemab has the potential for progranulin gene (GRN) mutations causative of Frontotemporal dementia (FTD) (FTD-GRN) research.
  • HY-124673
    AF40431
    		Inhibitor 98.00%
    AF40431, the first reported small-molecule ligand of sortilin, has an IC50 of 4.4 µM and a Kd of 0.7 µM . AF40431 is bound in the neurotensin-binding site of sortilin.
  • HY-153686
    BVFP
    		Inhibitor 98.12%
    BVFP binds to the PGRN588–593 peptide with a Kd of 20 μM. BVFP can disrupt PGRN-SORT1 binding. BVFP also inhibits SORT1-mediated rPGRN endocytosis.
  • HY-153688
    SORT-PGRN interaction inhibitor 3
    		Inhibitor
    SORT-PGRN interaction inhibitor 3 (Compound 13) is a SORT-PGRN interaction inhibitor (IC50: 0.17 μM). SORT-PGRN interaction inhibitor 3 can be used for research of neurodegenerative diseases.
  • HY-139668
    VGD071
    		Inhibitor
    VGD071, a sortilin-targeting compound, is a promising candidate for future studies using mouse breast cancer models.